WA-PATTERN-COMPUTER
17.6.2021 22:05:07 CEST | Business Wire | Press release
Pattern Computer,® Inc . (PCI) has developed a novel test for near real-time (15 sec) diagnosis of SARS-CoV-2 infections. In contrast with widely used antibody and PCR tests, which take at least 15 minutes to produce results, and require scarce reagents to process, the newly developed PCI method enables high-volume throughput of tests without requiring chemical reagents at difficult to service locations, such as company entrances, event venues, court houses, state and federal facilities, TSA screening areas and ports of entry.
“Having a simple, fast, easy to administer, high accuracy COVID-19 test will be critical for TSA and the airline carriers to increase passenger safety and confidence, as carriers deal with rising passenger loads and increased health security requirements,” said Bob Edwards, former CIO for United Airlines. “Pattern Computer’s new system appears to meet that need.”
Developed using the Pattern Discovery Engine™ (PDE) comprised of proprietary software methods and specially configured hardware, the initial results suggest this low-cost, high-volume COVID-19 test could create new opportunities for reducing transmission risk in high-headcount, high-density entertainment venues, large-scale events, office buildings, trains, busses, aircraft, and subways.
“As the world enters the next cycles of COVID lockdowns and flareups, there will be a pressing need for the companion technology to vaccines – the ability to detect true positive infections, and simultaneously reduce the incidence of false positives, coupled with higher reliability rates, delivered in real time. These are the required characteristics of a regimen of testing that will enable better containment of future outbreaks. The Pattern Computer team was able to apply the proven abilities of the Pattern Discovery Engine to take on this daunting challenge. We wanted to create a high-performance, extremely accurate, reagent-free, real-time alternative for testing in the world’s most important venues. This combination of proprietary hardware and software appears capable of meeting that critical need,” according to Mark R. Anderson, CEO of Pattern Computer.
Pattern Computer’s new test has been used to analyze data from symptomatic and asymptomatic patients between 10 and 80 years old. The reported balanced accuracy of the new test is >96%. The aspects of the testing that are worth noting: the Pattern team has been working on the problem for a few months, and is working with a dataset that numbers in the hundreds of data points. Competing organizations and teams have been working on the same problem for over a year with millions of data points, to only deliver tests that are 97% accurate.
The results from the Pattern tests are competitive with the performance of antibody tests currently in the market, which under ideal conditions (3 weeks after onset of symptoms) reports a balanced accuracy of 95%1 . In contrast to antibody tests, which are highly sensitive to timing--only 30% of people infected with SARS-CoV-2 tests positive 1 week after the onset of symptoms--the performance of PCI diagnosis is agnostic regarding how long the patient has been symptomatic.
“Pattern Computer has rapidly developed a reagent free SARS-CoV-2 diagnostic platform with an impressive level of accuracy. This technology has the potential to alter the landscape of disease diagnostics. Currently, they are focused on COVID-19, but their approach is applicable, in principle, to any disease. I suspect that, in the new future, as we walk through TSA security at an airport, part of the screen will be for infectious diseases. The implications of this technology for public safety and health, especially disease surveillance, are enormous,” said Prof. J. Ben Brown, UC Berkeley & Lawrence Berkeley National Laboratory.
PCI has built an initial model that predicts COVID-19 status (as determined by multi-target RT-PCR) of a patient based on its proprietary hardware measurements. Sensitivity and specificity are computed with 5-fold cross-validation.
PCI expects that as more data points are added to the PCI data base, particularly data from non-infected individuals, its technology will be able to match or exceed RT-PCR for accurate SARS-CoV-2 infection detection, with the reduced result time of 20 seconds rather than the current standard wait time of 30 minutes or more2 .
The foregoing contains statements about the Pattern Computer’s future that are not statements of historical fact. These statements are “forward-looking statements” for purposes of applicable securities laws and are based on current information and/or management's good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.
About Pattern Computer
Pattern Computer, Inc., a Seattle-area startup, uses its proprietary Pattern Discovery Engine to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems.
While the company is currently applying its computational platform to the challenging field of drug discovery, it is also making pattern discoveries for partners in several other sectors, including additional biomedical research, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance.
For more information on Pattern Computer Inc., visit: www.patterncomputer.com
For more information about Mark Anderson, visit: www.patterncomputer.com/founders/
Copyright © 2021 Pattern Computer, Inc. All Rights Reserved. Pattern Computer Inc., and PCI are trademarks of Pattern Computer, Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.
_________________________________________________
1
Antibody tests for identification of current and past infection with SARS‐CoV‐2 - Deeks, JJ - 2020 | Cochrane Library
, https://doi.org/10.1002/14651858.CD013652
, June 25, 2020
2
Covid-19: Bosch develops “fastest” PCR test in the world (msn.com)
, https://www.msn.com/en-ae/news/other/covid-19-bosch-develops-fastest-pcr-test-in-the-world/ar-BB1aNLVB
, August 11, 2020
View source version on businesswire.com: https://www.businesswire.com/news/home/20210617005847/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
